Topics
Glioblastoma | Treatment | Clinical trials | CAR-T-Cells
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > CAR-T-Cells
Bagley SJ, Binder ZA, Lamrani L,
Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA,
Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W,
Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan
S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K,
Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon
JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated
peripheral infusions of anti-EGFRvIII CAR T cells in combination
with pembrolizumab show no efficacy in glioblastoma: a phase 1
trial.
Nat
Cancer. 2024 Jan
12. doi:
10.1038/s43018-023-00709-6. PMID:
38216766. Interventional study˰ ˍ
Begley SL, O'Rourke DM, Binder ZA.
CAR
T Cell Therapy for Glioblastoma: A Review of the First Decade of
Clinical Trials.
Mol
Ther. 2025 Mar 7:S1525-0016(25)00178-9. doi:
10.1016/j.ymthe.2025.03.004. PMID:
40057825. Review. ˍ
**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C,
Wen H, Chang LJ, Ma H, Cai Q.
Preliminary
exploration of PSMA CAR-T combined with GD2 CAR-T for the
treatment of refractory/relapsed gliomas.
J
Transl Med. 2025 May 27;23(1):591. doi:
10.1186/s12967-025-06523-1. PMID:
40420236. Interventional study. ˍ
Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D,
Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ,
Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L,
Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S,
Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F,
Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT,
Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM.
Intracerebroventricular bivalent CAR T
cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma:
a phase 1 trial.
Nat
Med. 2025 Jun 1. doi:
10.1038/s41591-025-03745-0. PMID:
40451950. Interventional study. ˍ
Chan JTN, Henley-Waters J, Kayhanian S.
Chimeric
antigen receptor (CAR)-T-cell therapy for glioblastoma: what can
we learn from the early clinical trials? A systematic
review.
Neurooncol
Adv. 2025 Jun 3;7(1):vdaf115. doi:
10.1093/noajnl/vdaf115. PMID:
40626039. Review. ˍ
AI
Overview
Barish
ME, Aftabizadeh M, Hibbard J, Blanchard MS, Ostberg JR, Wagner JR,
Manchanda M, Paul J, Stiller T, Aguilar B, Starr R, Arvanitis L,
Ressler JA, Kilpatrick J, Kong Y, Wang D, Forman SJ, D'Apuzzo M,
Brown CE, Badie B.
Chlorotoxin-directed
CAR T cell therapy for recurrent glioblastoma: Interim clinical
experience demonstrating feasibility and safety.
Cell
Rep Med.
2025 Aug 15;6(8):102302. doi:
10.1016/j.xcrm.2025.102302. PMID:
40818458. Interventional study. ˍ
ClinicalTrrials.gov
ID: NCT04214392.
Habibi MA, Nejati N, Najafi MB, Khodadadiyan A, Dashti M,
Lorestani P, Karimizadeh Z, Ahmadpour M, Kalantari A, Jokar-Derisi
A, Maghsood F, Robat-Jazi B, Ebrahimi E, Ahmadpour S, Tavakolpour
S.
Enhancing T cell infiltration in
glioblastoma: a review article on challenges and therapeutic
strategies.
Cancer
Treat Res Commun. 2025 Sep 9;45:100999. doi:
10.1016/j.ctarc.2025.100999. PMID:
40961824. Review. ˍ
Freeburg NF, Chafamo D, Konanur Gopikrishna G, Murphy RM, Peng JJ,
Parthasarathy S, Dumont S, Estrada EG, Logun MT, Sun Y, Wang X,
Grover P, Rodriguez JL, Zhang DL, Park K, Fu Y, Ben Hamouda N,
Hernandez-Verdin I, Lamrani L, Hicks KA, Cooper NA, Ekwegbara C,
Bawden EG, Waterfall JJ, Fuentealba J, Alcantara M, Seykora JT,
Prouty SM, Barrett D, Banerjee E, Cox A, Assenmacher CA, Macia C,
Yin M, Carpenter EL, Ming GL, Sautès-Fridman C, Fridman WH,
Tartour E, Wherry EJ, Amigorena S, Fraietta JA, Nasrallah MP, Song
H, Miller TE, Bagley SJ, O'Rourke DM, Binder ZA, Alanio C,
Silverbush D.
The
critical role of the endogenous immune compartment after CAR T
cell therapy in recurrent GBM.
Cell.
2026 Jun 15:S0092-8674(26)00585-4. doi:
10.1016/j.cell.2026.05.026. PMID:
42296961. Trial
registration ID: NCT05168423.
ˍ